Beigene Ltd
ONC307.510USD
+19.410+6.74%
終値 08/13, 16:00（ET）15分遅れの株価
31.06B時価総額
損失額直近12ヶ月PER
詳細情報 Beigene Ltd 企業名
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
企業情報
企業コードONC
会社名BeOne Medicines AG
上場日- -
最高経営責任者「CEO」Mr. John Victor Oyler
従業員数11000
証券種類Ordinary Share
決算期末- -
本社所在地c/o BeOne Medicines I GmbH
都市BASEL
証券取引所The Toronto Stock Exchange
国Switzerland
郵便番号4051
電話番号41616851900
ウェブサイト
企業コードONC
上場日- -
最高経営責任者「CEO」Mr. John Victor Oyler
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
-33.42%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
-33.42%
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
地域別USD
会社名
収益
比率
United States
567.21M
50.77%
China
399.59M
35.76%
Europe
118.55M
10.61%
ROW
31.92M
2.86%
事業別
地域別
事業別USD
会社名
収益
比率
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Other
-1.03B
-92.23%
株主
更新時刻: 3 hours ago
更新時刻: 3 hours ago
株主統計
種類
株主統計
株主統計
比率
Amgen Inc
17.22%
Baker Bros. Advisors LP
8.00%
PRIMECAP Management Company
4.62%
Capital International Investors
4.44%
Fidelity Management & Research Company LLC
3.05%
Other
62.67%
株主統計
株主統計
比率
Amgen Inc
17.22%
Baker Bros. Advisors LP
8.00%
PRIMECAP Management Company
4.62%
Capital International Investors
4.44%
Fidelity Management & Research Company LLC
3.05%
Other
62.67%
種類
株主統計
比率
Investment Advisor
18.35%
Corporation
17.23%
Hedge Fund
10.86%
Investment Advisor/Hedge Fund
4.59%
Sovereign Wealth Fund
1.32%
Research Firm
0.88%
Pension Fund
0.21%
Bank and Trust
0.04%
Family Office
0.02%
Other
46.51%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Amgen Inc
18.94M
17.28%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.03%
--
--
Mar 31, 2025
PRIMECAP Management Company
5.06M
4.61%
-43.40K
-0.85%
Mar 31, 2025
Capital International Investors
5.09M
4.64%
-1.02M
-16.72%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.36M
3.07%
+1.58M
+88.38%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.41M
1.29%
-80.54K
-5.39%
Mar 31, 2025
T. Rowe Price International Ltd
1.30M
1.19%
-143.22K
-9.92%
Mar 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
May 09, 2025
Temasek Holdings Pte. Ltd.
993.75K
0.91%
-531.58K
-34.85%
Mar 31, 2025
Citadel Advisors LLC
982.16K
0.9%
+665.05K
+209.72%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
First Trust NYSE Arca Biotechnology Index Fund
3.3%
Tema Oncology ETF
2.75%
VanEck Biotech ETF
2.72%
Global X Aging Population ETF
1.87%
Virtus LifeSci Biotech Products ETF
1.69%
iShares Biotechnology ETF
1.4%
Invesco Nasdaq Biotechnology ETF
1.11%
ProShares Ultra Nasdaq Biotechnology
1.11%
Innovator IBD 50 Fund ETF
0.9%
National Security Emerging Markets Index ETF
0.77%
詳細を見る
First Trust NYSE Arca Biotechnology Index Fund
比率3.3%
Tema Oncology ETF
比率2.75%
VanEck Biotech ETF
比率2.72%
Global X Aging Population ETF
比率1.87%
Virtus LifeSci Biotech Products ETF
比率1.69%
iShares Biotechnology ETF
比率1.4%
Invesco Nasdaq Biotechnology ETF
比率1.11%
ProShares Ultra Nasdaq Biotechnology
比率1.11%
Innovator IBD 50 Fund ETF
比率0.9%
National Security Emerging Markets Index ETF
比率0.77%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
